Literature DB >> 34743224

Interpreting Quality Improvement When Introducing New Technology: A Collaborative Experience in ASD Device Closures.

Mary J Yeh1, Lauren Shirley1, David T Balzer2, Brian A Boe3, Howaida El-Said4, Susan Foerster5, Kimberlee Gauvreau1, Todd M Gudausky5, Michael R Hainstock6, Nicola Maschietto1, George T Nicholson7, Brian P Quinn1, Shabana Shahanavaz8, Sara Trucco9, Wendy Whiteside10, Lisa Bergersen11.   

Abstract

The objective of this study was to evaluate the impact of the regular introduction of new technologies into interventional cardiac catheterization procedures, in this case new atrial septal defect (ASD) closure devices, while conducting a multi-center collaborative initiative to reduce radiation usage during all procedures. Data were collected prospectively by 8 C3PO institutions between January 1, 2014 and December 31, 2017 for ASD device closure procedures in the cardiac catheterization lab during a quality improvement (QI) initiative aimed at reducing patient radiation exposure. Radiation exposure was measured in dose area product per body weight (µGy*m2/kg). Use of proposed practice change strategies at the beginning and end of the QI intervention period was assessed. Radiation exposure was summarized by institution and by initial type of device used for closure. This study included 602 ASD device closures. Without changes in patient characteristics, total fluoroscopy duration, or number of digital acquisitions, median radiation exposure decreased from 37 DAP/kg to 14 DAP/kg from 2014 to 2017. While all individual centers decreased overall median DAP/kg, the use of novel devices for ASD closure correlated with a temporary period of worsening institutional radiation exposure and increased fluoroscopy time. The introduction of new ASD closure devices resulted in increased radiation exposure during a QI project designed to reduce radiation exposure. Therefore, outcome assessment must be contextualized in QI projects, hospital evaluation, and public reporting, to acknowledge the expected variation during innovation and introduction of novel therapies.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Congenital heart disease; Outcome metrics; Pediatric intervention; Quality improvement; Radiation risk

Mesh:

Year:  2021        PMID: 34743224     DOI: 10.1007/s00246-021-02762-3

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  8 in total

1.  Adverse event rates in congenital cardiac catheterization - a multi-center experience.

Authors:  Lisa Bergersen; Audrey Marshall; Kimberlee Gauvreau; Robert Beekman; Russel Hirsch; Susan Foerster; David Balzer; Julie Vincent; William Hellenbrand; Ralf Holzer; John Cheatham; John Moore; James Lock; Kathy Jenkins
Journal:  Catheter Cardiovasc Interv       Date:  2010-02-15       Impact factor: 2.692

2.  Rebuttal.

Authors:  Howaida El-Said
Journal:  Catheter Cardiovasc Interv       Date:  2015-05-27       Impact factor: 2.692

3.  How Slow Can We Go? 4 Frames Per Second (fps) Versus 7.5 fps Fluoroscopy for Atrial Septal Defects (ASDs) Device Closure.

Authors:  Gurumurthy Hiremath; Jeffery Meadows; Phillip Moore
Journal:  Pediatr Cardiol       Date:  2015-01-25       Impact factor: 1.655

4.  Longitudinal Improvements in Radiation Exposure in Cardiac Catheterization for Congenital Heart Disease: A Prospective Multicenter C3PO-QI Study.

Authors:  Brian P Quinn; Priscila Cevallos; Aimee Armstrong; David Balzer; Howaida El-Said; Susan Foerster; Andrew C Glatz; Andrea Goodman; Bryan Goldstein; Michael Hainstock; Dana Janssen; Jacqueline Kreutzer; Larry Latson; Ryan Leahy; Christopher Petit; Shabana Shahanavaz; Sara Trucco; Wendy Whiteside; Jeffrey D Zampi; Lisa Bergersen
Journal:  Circ Cardiovasc Interv       Date:  2020-05-15       Impact factor: 6.546

5.  Effects of reducing frame rate from 7.5 to 4 frames per second on radiation exposure in transcatheter atrial septal defect closure.

Authors:  Younes Boudjemline
Journal:  Cardiol Young       Date:  2018-07-30       Impact factor: 1.093

6.  Reduction of radiation exposure in transcatheter atrial septal defect closure: How low must we go?

Authors:  Fidelio Sitefane; Sophie Malekzadeh-Milani; Olivier Villemain; Magalie Ladouceur; Younes Boudjemline
Journal:  Arch Cardiovasc Dis       Date:  2017-10-31       Impact factor: 2.340

7.  Amplatzer Piccolo Occluder clinical trial for percutaneous closure of the patent ductus arteriosus in patients ≥700 grams.

Authors:  Shyam K Sathanandam; Dan Gutfinger; Laura O'Brien; Thomas J Forbes; Matthew J Gillespie; Darren P Berman; Aimee K Armstrong; Shabana Shahanavaz; Thomas K Jones; Brian H Morray; Toby A Rockefeller; Henri Justino; David G Nykanen; Evan M Zahn
Journal:  Catheter Cardiovasc Interv       Date:  2020-05-20       Impact factor: 2.692

8.  Procedural Risk in Congenital Cardiac Catheterization (PREDIC3T).

Authors:  Brian P Quinn; Mary Yeh; Kimberlee Gauvreau; Fatima Ali; David Balzer; Oliver Barry; Sarosh Batlivala; Darren Berman; Susan Foerster; Bryan Goldstein; Michael Hainstock; Ralf Holzer; Dana Janssen; Michael L O'Byrne; Lauren Shirley; Sara Trucco; Wendy Whiteside; Lisa Bergersen
Journal:  J Am Heart Assoc       Date:  2021-12-22       Impact factor: 6.106

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.